Krzysztof Masternak

This inventor holds 15 USPTO granted patents and 5 published patent applications, plus 4 CIPO patents and 5 EPO patents. Top assignees: Novimmune Sa, Genentech, Inc.. Active years: 2012-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Krzysztof Masternak. Retrieved from https://idiyas.com/inventor/krzysztof-masternak

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 5)

% Patents Active = 60.0

CIPO Patents = 4 (Patent Applications = 6)

EPO Patents = 5 (Patent Applications = 12)

Average Co-Inventor Count = 2.9

ph-index = 4

Forward Citations = 44(Granted Patents)

Company Filing History:

Years Active: 2012-2026

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12583922 - BISPECIFIC ANTIBODIES TARGETING CD47 AND PD-L1 AND METHODS OF USE THEREOF (2026-03-24),

2. 12448444 - Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof (2025-10-21),

3. 11840553 - Anti-CD47 antibodies and methods of use thereof (2023-12-12),

4. 11401299 - Generating multispecific antibody mixtures and methods of uses thereof (2022-08-02),

5. 11261262 - Readily isolated bispecific binding molecules with native format having mutated constant regions (2022-03-01),

6. 11260117 - Anti-CD47 x anti-mesothelin antibodies and methods of use thereof (2022-03-01),

7. 11059910 - Anti-CD47 antibodies and methods of use thereof (2021-07-13),

8. 10494446 - Readily isolated bispecific antibodies with native immunoglobulin format (2019-12-03),

9. 9815909 - Readily isolated bispecific antibodies with native immunoglobulin format (2017-11-14),

10. 9650437 - Nucleic acid encoding and method of producing anti-IL-17A/IL-17F cross-reactive antibodies (2017-05-16),

11. 9475873 - Nucleic acids encoding anti-IL-17F antibodies and methods of use thereof (2016-10-25),

12. 8771697 - Methods of treatment using anti-IL-17A/IL-17F cross-reactive antibodies (2014-07-08),

13. 8715669 - Anti-IL-17A/IL-17F cross-reactive antibodies (2014-05-06),

14. 8609093 - Methods of treatment using anti-IL-17F antibodies (2013-12-17),

15. 8137671 - Anti-IL-17F antibodies (2012-03-20),

Title: Krzysztof Masternak: Pioneering Innovator in Antibody Research

Introduction: Krzysztof Masternak, an accomplished inventor based in Mollens, Switzerland, has made significant contributions to the field of monoclonal antibodies with a total of 13 patents to his name. His work has focused on the development of innovative therapeutic strategies, particularly in the realm of immune modulation.

Latest Patents: Krzysztof Masternak's latest patents showcase his expertise in antibody technologies. One notable invention is related to anti-CD47 antibodies and methods of use thereof. This patent encompasses monoclonal and/or monovalent antibodies that specifically bind to CD47 and CD19, as well as the creation of novel bispecific monoclonal antibodies which carry distinct specificities for each binding site. Additionally, he has developed a patent for generating multispecific antibody mixtures, which involves a subset of antibodies that are isolated from a combination of monospecific and bispecific antibodies, all sharing the same common heavy chain. These inventions are aimed at enhancing therapeutic applications across various medical indications.

Career Highlights: Throughout his illustrious career, Krzysztof has collaborated with renowned organizations, including Novimmune SA and Genentech, Inc. His innovative approaches in antibody research have not only advanced the understanding of immune responses but have also paved the way for new treatment options in various diseases.

Collaborations: Krzysztof has worked alongside esteemed colleagues, such as Francois Rousseau and Nicolas Fischer, contributing to a vibrant environment of scientific collaboration. Their combined efforts in research and development have played a vital role in pushing the boundaries of what's possible in antibody therapy.

Conclusion: Krzysztof Masternak stands as a testament to the power of innovation in scientific research. His numerous patents and collaborative efforts underline his dedication to improving healthcare through advanced antibody technologies. With a commitment to exploration and discovery, he continues to influence the future of biomedical research and therapeutic development.

Profile summary based on public USPTO records.